The Claim
In patients with mild Alzheimer’s disease, treatment with laromestrocel is associated with a 61.9% reduction in left hippocampal atrophy over 39 weeks compared to placebo, and there is a statistically significant correlation (R=0.41, P=0.0075) between preservation of hippocampal volume and cognitive stability as measured by MMSE-2.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with mild Alzheimer’s disease, laromestrocel treatment is associated with a 61.9% reduction in left hippocampal atrophy over 39 weeks compared to placebo, and greater preservation of hippocampal volume is correlated with more stable cognitive performance on the MMSE-2 test.
See the scientific wording
In patients with mild Alzheimer’s disease, treatment with laromestrocel is associated with a 61.9% reduction in left hippocampal atrophy over 39 weeks compared to placebo, with a statistically significant correlation (R=0.41, P=0.0075) between hippocampal volume preservation and cognitive stability as measured by MMSE-2.
Laromestrocel releases molecules that stop a key blood vessel receptor from breaking apart, which keeps blood vessels in the brain healthy and reduces inflammation. This protects brain cells in the memory center from dying, so the brain doesn't shrink as much and memory stays stable.
What the research says
1 studyIn early Alzheimer’s, a treatment called laromestrocel helped keep the memory center of the brain from shrinking as much as it normally does, and people who got the treatment also stayed sharper on memory tests.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.